Sugi Predict

Sugi Predict / Compounds / SCHEMBL34456

SCHEMBL34456

SCHEMBL34456

O=C1N[C@H]2[C@H](CS[C@H]2CCCCC(=O)OC(=O)CI)N1

nearest known ligand 0.72

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 6/20 0.72
▸ MEN1 O00255 1/20 0.67
▸ ABL1 P00519 1/20 0.67
▸ LMNA P02545 1/20 0.67
▸ PKM P14618 1/20 0.67
▸ IDE P14735 1/20 0.67
▸ MAPK1 P28482 1/20 0.67
▸ KMT2A Q03164 1/20 0.67
▸ RIN1 Q13671 1/20 0.67
▸ L3MBTL1 Q9Y468 1/20 0.67
▸ HLCS P50747 6/20 0.59
▸ CA12 O43570 5/20 0.49
▸ CA1 P00915 5/20 0.49
▸ CA2 P00918 5/20 0.49
▸ CA9 Q16790 5/20 0.49
▸ HPSE Q9Y251 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21176811 0.94 TDP1 (0.81) TDP1MEN1ABL1LMNAPKM
SCHEMBL28119479 0.94 TDP1 (0.81) TDP1MEN1ABL1LMNAPKM
SCHEMBL28283183 0.94 TDP1 (0.81) TDP1MEN1ABL1LMNAPKM
SCHEMBL21114407 0.94 TDP1 (0.81) TDP1MEN1ABL1LMNAPKM
SCHEMBL22265330 0.92 TDP1 (0.79) TDP1MEN1ABL1LMNAPKM
SCHEMBL28516361 0.89 TDP1 (0.77) TDP1MEN1ABL1LMNAPKM
SCHEMBL20473406 0.88 TDP1 (0.72) TDP1MEN1ABL1LMNAPKM
SCHEMBL7258731 0.88 TDP1 (0.72) TDP1MEN1ABL1LMNAPKM
SCHEMBL2589782 0.88 TDP1 (0.72) TDP1MEN1ABL1LMNAPKM
SCHEMBL28157478 0.88 TDP1 (0.76) TDP1MEN1ABL1LMNAPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 275 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1238115-B1 PROCESS FOR LABELING A RIBONUCLEIC ACID, AND LABELED RNA FRAGMENTS WHICH ARE OBTAINED THEREBY BIO MERIEUX (FR) 2009-10-14 — — EP claimed
CN-1166784-C Method for labeling ribonucleic acid and labeled RNA fragment obtained thereby �Ȱ���ϣ�¹�˾ 2004-09-15 — — CN claimed
CN-1391616-A Method for labeling ribonucleic acid and labeled RNA fragment obtained thereby BIO MERIEUX (FR) 2003-01-15 — — CN claimed
US-6489114-B2 FORMING RNA FRAGEMNTS, FIXING A FIRST LIGAND TO A TERMINAL PHOSPHATE THAT HAS BEEN RELEASED DURING FRAGMENTATION, AND BINDING LABELING AGENTS TO THE FIRST LIGAND BIO MERIEUX (FR) 2002-12-03 — — US claimed
EP-1238115-A1 PROCESS FOR LABELING A RIBONUCLEIC ACID, AND LABELED RNA FRAGMENTS WHICH ARE OBTAINED THEREBY BIO MERIEUX (FR) 2002-09-11 — — EP claimed
US-20010044105-A1 Process for labeling a ribonucleic acid, and labeled RNA fragments which are obtained thereby AFFYMETRIX, INC. 2001-11-22 — — US claimed
WO-2001044506-A1 PROCESS FOR LABELING A RIBONUCLEIC ACID, AND LABELED RNA FRAGMENTS WHICH ARE OBTAINED THEREBY BIO MERIEUX (FR) 2001-06-21 — — WO claimed
CN-119552249-A Cysteine engineered antibodies and conjugates 基因泰克公司 2025-03-04 — — CN disclosed
US-20250025469-A1 COMBINATION THERAPIES INFINITY PHARMACEUTICALS, INC. 2025-01-23 — — US disclosed
CN-114246952-B Cysteine engineered antibodies and conjugates 基因泰克公司 2024-11-22 — — CN disclosed
US-20240325398-A1 COMBINATION THERAPIES INFINITY PHARMACEUTICALS, INC. 2024-10-03 — — US disclosed
US-20240218050-A1 Cysteine Engineered Antibodies and Conjugates GENENTECH, INC. (US) 2024-07-04 — — US disclosed
US-11944631-B2 Combination therapies INFINITY PHARMACEUTICALS, INC. (US) 2024-04-02 — — US disclosed
EP-0411018-A1 DETECTION, QUANTITATION AND CLASSIFICATION OF RAS PROTEINS IN BODY FLUIDS AND TISSUES. DU PONT (US) 1991-02-06 — — EP disclosed
EP-0404783-A4 IMMUNOASSAYS USING MONOCLONAL ANTIBODIES DIRECTED AGAINST NATURAL BINDING PROTEINS — 1991-01-23 — — EP disclosed
EP-0404783-A1 IMMUNOASSAYS USING MONOCLONAL ANTIBODIES DIRECTED AGAINST NATURAL BINDING PROTEINS E.I. DU PONT DE NEMOURS AND COMPANY (US) 1991-01-02 — — EP disclosed
WO-1989011100-A1 ASSAY DEVICE AND IMMUNOASSAY E.I. DU PONT DE NEMOURS AND COMPANY (US) 1989-11-16 — — WO disclosed
WO-1989010565-A1 DETECTION, QUANTITATION AND CLASSIFICATION OF RAS PROTEINS IN BODY FLUIDS AND TISSUES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1989-11-02 — — WO disclosed
WO-1989007271-A1 IMMUNOASSAYS USING MONOCLONAL ANTIBODIES DIRECTED AGAINST NATURAL BINDING PROTEINS E.I. DU PONT DE NEMOURS AND COMPANY (US) 1989-08-10 — — WO disclosed
EP-0310132-A2 Immunoassay utilizing IgG capture antibody and multiple monoclonal antibody detection system E.I. DU PONT DE NEMOURS AND COMPANY (US) 1989-04-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250025469-A1 COMBINATION THERAPIES BCL2, BAK1, BCL3 TDP1 2016/4885MEN1 2809/4885ABL1 285/4885
US-20240218050-A1 Cysteine Engineered Antibodies and Conjugates CTH, LNPEP, CARS1 TDP1 3036/4885MEN1 4034/4885ABL1 109/4885
US-11944631-B2 Combination therapies BCL2, BAK1, BCL3 TDP1 2016/4885MEN1 2809/4885ABL1 285/4885
US-20240325398-A1 COMBINATION THERAPIES HDAC1, HDAC4, HDAC2 TDP1 855/4885MEN1 2508/4885ABL1 1083/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.